[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626843":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":7,"responsibleParty":24,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":7,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":7,"studyType":39,"phases":7,"briefSummary":40,"conditions":41,"keywords":7,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":7},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Immunotherapy plus chemotherapy","The neoadjuvant therapy regimen for muscle-invasive bladder cancer is the GC regimen. This study does not alter the patients' neoadjuvant therapy regimen but adds toripalimab to the selected neoadjuvant treatment. After MDT discussion, eligible patients will receive GC combined with immunotherapy therapy.",[14],"Immunotherapy combined with chemotherapy",[16],{"name":17,"affiliation":5,"role":18},"Xiongjun Ye","STUDY_CHAIR",[20],{"name":17,"role":21,"phone":22,"phoneExt":7,"email":23},"CONTACT","13910380916","yexiongjun@cicams.cn",{"type":25,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100626843","remodeling-of-mhc-related-immune-microenvironment-in-mibc-after-neoadjuvant-therapy-100626843",false,"NCT07440901","Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy","An Exploratory Study on the Remodeling of MHC-related Tumor Immune Microenvironment in Patients With Muscle-invasive Bladder Cancer After Neoadjuvant Therapy","Inclusion Criteria:\n\n* Male or female, aged ≥18 years.\n* Expected survival ≥12 weeks.\n* Diagnosed by histopathology as muscle-invasive bladder urothelial carcinoma (MIBC) without upper urothelial carcinoma.\n* Clinical stage (cT2-T4a, N0-1, M0) and no distant metastasis as evaluated by imaging.\n* The subjects were assessed by urologists as tolerable and planned radical cystectomy.\n* ECOG Physical Condition 0-2.\n\nExclusion Criteria:\n\n* Patients with previous malignant tumors were not eligible to participate in the study unless they had achieved complete remission for at least 5 years prior to enrollment and did not require additional treatment or did not require additional treatment during the study.\n* Combined with serious internal medical diseases including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc.\n* Patients with insufficient communication, understanding and cooperation, or poor compliance, cannot be guaranteed to complete follow-up as required.","ALL","18 Years","75 Years",{"count":37,"type":38},30,"ESTIMATED","OBSERVATIONAL","In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.",[42],"Muscle-invasive Bladder Cancer","NOT_YET_RECRUITING","2026-02-25",{"date":46,"type":47},"2026-02-27","ACTUAL",{"date":49,"type":38},"2026-02-01",{"date":51,"type":38},"2027-05-01",{"name":5,"class":6}]